Oral Answers to Questions
Debate between Nigel Adams and Alun Cairns(4 years ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Alun Cairns (Vale of Glamorgan) (Con)
The Minister for Europe is aware that my 18-year-old constituent, Tom Channon, tragically died at the Eden Roc complex in Mallorca in July 2018. That followed a similar death of Tomas Hughes, just weeks earlier. I believe there is a strong criminal case to be pursued for prosecution for negligence, and on 10 July this year I wrote to the president of the provincial court. I have pursued the matter persistently, but I still have not received a reply. Covid will have played a part, but does the Minister agree that waiting five months after the deaths of two 18-year-olds, two years earlier, is wholly unacceptable?
Nigel Adams
My right hon. Friend is right to raise that case. Deaths abroad of our constituents are always tragic, and our consular staff at post have spoken with the president of the provisional court in Palma. We have asked him for a response to my right hon. Friend’s letter. He is right to point out that there are some enormous workloads as a result of the covid pandemic, but the president has assured us that he will respond to the letter in due course. We will continue to push on behalf of my right hon. Friend and his constituents.
Oral Answers to Questions
Debate between Nigel Adams and Alun Cairns(14 years ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Nigel Adams (Selby and Ainsty) (Con)
1. What recent assessment he has made of the effectiveness of the operation of the interim cancer drugs fund; and if he will make a statement.
Alun Cairns (Vale of Glamorgan) (Con)
12. What recent representations he has received on the operation of the interim cancer drugs fund; and if he will make a statement.
The Secretary of State for Health (Mr Andrew Lansley)
Clinically led arrangements are in place in all strategic health authorities for determining the best use of the additional funds that we have made available for cancer drugs from 1 October 2010. Information provided by SHAs shows that, as of 15 November, funding had been agreed for the treatment of more than 250 patients in England. I have received representations from hon. Members, noble Lords, and members of the public on how the interim arrangements for cancer drugs funding are operating. Many of those representations have welcomed the additional support we are giving to cancer patients in need.